Home / Insights / Hatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

Hatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

12 December 2013

Posted in — OneVentures

Share

Learn More

Share

You may also like

Bivacor team

21 February 2024

Healthcare

Australian engineer invents first artificial heart


Bivacor team

29 November 2023

Healthcare

US FDA Grants the BiVACOR Total Artificial Heart IDE Approval for First-in-Human Early Feasibility Study


18 June 2023

Healthcare

Vaxxas opens world-class manufacturing facility to produce needle-free vaccine patch


View All

Ventured. Gained.
decor